Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET).
Saved in:
| Title: | Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET). |
|---|---|
| Authors: | Giuliani, Meredith E.1 (AUTHOR) Meredith.Giuliani@rmp.uhn.ca, Filion, Edith2 (AUTHOR), Faria, Sergio3 (AUTHOR), Kundapur, Vijayananda4 (AUTHOR), (Toni) Vu, Thi Trinh Thuc2 (AUTHOR), Lok, Benjamin H.1 (AUTHOR), Raman, Srinivas1 (AUTHOR), Bahig, Houda2 (AUTHOR), Laba, Joanna M.5 (AUTHOR), Lang, Pencilla5 (AUTHOR), Louie, Alexander V.6 (AUTHOR), Hope, Andrew1 (AUTHOR), Rodrigues, George B.5 (AUTHOR), Bezjak, Andrea1 (AUTHOR), Campeau, Marie-Pierre2 (AUTHOR), Duclos, Marie3 (AUTHOR), Bratman, Scott1 (AUTHOR), Swaminath, Anand7 (AUTHOR), Salunkhe, Rohan1 (AUTHOR), Warner, Andrew5 (AUTHOR) |
| Source: | International Journal of Radiation Oncology, Biology, Physics. Nov2024, Vol. 120 Issue 3, p669-677. 9p. |
| Subjects: | Stereotactic radiotherapy, Non-small-cell lung carcinoma, Interstitial lung diseases, Pulmonary veins, Pulmonary artery |
| Abstract: | The use of stereotactic body radiation therapy for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (NCT03306680) aimed to determine the maximally tolerated dose of stereotactic body radiation therapy for ultracentral non-small cell lung carcinoma, using a time-to-event continual reassessment methodology. Patients with T1-3N0M0 (≤6 cm) non-small cell lung carcinoma were eligible. The maximally tolerated dose was defined as the dose of radiation therapy associated with a ≤30% rate of grade (G) 3 to 5 prespecified treatment-related toxicity occurring within 2 years of treatment. The starting dose level was 60 Gy in 8 daily fractions. The dose-maximum hotspot was limited to 120% and within the planning tumor volume; tumors with endobronchial invasion were excluded. This primary analysis occurred 2 years after completion of accrual. Between March 2018 and April 2021, 30 patients were enrolled at 5 institutions. The median age was 73 years (range, 65-87) and 17 (57%) were female. Planning tumor volume was abutting proximal bronchial tree in 19 (63%), esophagus 5 (17%), pulmonary vein 1 (3.3%), and pulmonary artery 14 (47%). All patients received 60 Gy in 8 fractions. The median follow-up was 37 months (range, 8.9-51). Two patients (6.7%) experienced G3-5 adverse events related to treatment: 1 patient with G3 dyspnea and 1 G5 pneumonia. The latter had computed tomography findings consistent with a background of interstitial lung disease. Three-year overall survival was 72.5% (95% CI, 52.3%-85.3%), progression-free survival 66.1% (95% CI, 46.1%-80.2%), local control 89.6% (95% CI, 71.2%-96.5%), regional control 96.4% (95% CI, 77.2%-99.5%), and distant control 85.9% (95% CI, 66.7%-94.5%). Quality-of-life scores declined numerically over time, but the decreases were not clinically or statistically significant. : Sixty Gy in 8 fractions, planned and delivered with only a moderate hotspot, has a favorable adverse event rate within the prespecified acceptability criteria and results in excellent control for ultracentral tumors. [ABSTRACT FROM AUTHOR] |
| Copyright of International Journal of Radiation Oncology, Biology, Physics is the property of Pergamon Press - An Imprint of Elsevier Science and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
Be the first to leave a comment!
